Both companies shared aging clock data at a research conference, including Novo blood samples from 10,052 people. Geneticist Steve Horvath called the effect strong.
Recap by typeshit. Full story at New York Post.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Tino Bourse points to new Wegovy data showing a large cut in liver fat in patients with obesity, plus continued oral version results, as possible good news for Novo stock.
The free session covers nutrition, exercise, side effects and common myths for people curious about GLP-1 medications. A local event listing.
Loading…